Focused ultrasound with pembrolizumab for recurrent glioblastoma
Treatments studied
Part of Cancer clinical trials.
This trial tests a new way of treating recurrent glioblastoma that has a specific genetic feature called mismatch repair deficiency. It uses focused ultrasound to help the immunotherapy drug pembrolizumab work better against the tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with a type of brain tumor called glioblastoma (GBM), specifically the IDH-wildtype kind.
- Your tumor tested positive for mismatch repair deficiency (MMR-d), a specific genetic feature.
- You have already had standard treatment for GBM, including surgery, radiation, and the chemotherapy drug temozolomide (TMZ).
- You have had a repeat surgery for a recurrent tumor.
- You are at least 18 years old and are in good overall health (KPS > 70).
- Your blood counts and organ function meet certain minimum levels.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a device that opens the blood-brain barrier using ultrasound, allowing chemotherapy to reach the brain tumor better. It compares this approach to standard chemotherapy for people whose glioblastoma has returned.
This study tests whether adding focused ultrasound to the standard drug Avastin (bevacizumab) can help treat recurrent glioblastoma. The ultrasound may help more of the drug reach the tumor.
This trial tests a new way to take a tiny tissue sample from a suspected glioblastoma using ultrasound, to improve noninvasive detection. You may be able to get this targeted sample while you’re already planning surgery for tumor removal.
This trial tests whether adding the Optune device (a wearable electric field therapy) to standard chemotherapy (temozolomide) and the immunotherapy drug pembrolizumab can help people with newly diagnosed glioblastoma live longer. You may be able to join if you've completed initial radiation and chemo, and have not received certain immunotherapies before.
This trial tests a new approach that uses a light-sensitive drug and low-intensity ultrasound to make standard chemotherapy more effective for glioblastoma. If you have completed initial treatment with radiation and temozolomide without the tumor growing, you may be eligible.
This trial studies different treatment regimens for people with glioblastoma that is either newly diagnosed or has come back. It aims to find which treatment approach works best for controlling the tumor and improving outcomes.
Hear when a new Glioblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.